Companies

NBE Therapeutics: Cancer drugs with a twist for fewer side effects

Ulf Grawunder, CEO NBE Therapeutics

At the Technologiepark Basel, you get a plug-and-play set-up, a dynamic environment and first-class infrastructure at an affordable price.

Michael Bauer, CEO Cellestia Biotech AG

abel-systems is a software engineering and IT consulting company specialized in custom web and mobile development. abel-systems develops and distributes the process- and document-management solution QM-Pilot. Furthermore we provide IT solutions for content management, web and mobile apps, as well as the development of individual solutions with modern technologies.

abel-systems

Hochbergerstrasse 60C

4057 Basel

+41 61 205 60 21

info@abel-systems.ch

http://www.abel-systems.ch

Artidis AG focuses on development and commercialization of ARTIDIS (AUTOMATED AND RELIABLE TISSUE DIAGNOSTICS) nanotechnology platform for rapid diagnostics and treatment optimization. ARTIDIS is based on the atomic force microscope, which can determine the (nano)mechanical properties of native tissue by using a fine, nanometer-scale probe. able to examine tissue biopsies within an hour. By providing such nanomechanical profile of patient biopsy sample, ARTIDIS allows for rapid diagnosis of benign or malignant tumors and consequently optimization of treatment for cancer patients.

ARTIDIS AG

Hochbergerstrasse 60C

4057 Basel

Aurealis Pharma is a Swiss-Finnish biopharmaceutical company with a technology platform facilitating combination therapy embedded in one single product that can be administered in a safe, efficient and cost-effective way. Safe food-grade lactic acid bacteria release multiple therapeutic human proteins locally in diseased tissue. Our first products are immuno-therapeutics to treat patients with chronic inflammatory wounds and cancer indications.

Aurealis Pharma AG.

Hochbergerstrasse 60C

4057 Basel

http://www.aurealispharma.com

BioVersys switches off bacterial drug resistance, thus reactivating approved antibiotics.

We develop small chemical molecules, which switch off drug resistance on a gene regulatory level within bacteria, so called TRIC’s (Transcriptional Regulator Inhibitory Compounds). Current pipeline: Gram negative and positive bacteria; Tuberculosis.

BioVersys AG

Hochbergerstrasse 60C

4057 Basel

http://www.bioversys.com

Cellestia Biotech S.A. is a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signalling pathway. CB-103 is a novel, first-in-class, oral pan-Notch inhibitor for treatment of NOTCH dependent lukemia, lymphoma and solid tumors.

Cellestia Biotech S.A.

Hochbergerstrasse 60C

4057 Basel

https://www.cellestia.com/

As a global leader in supercomputing, Cray provides highly advanced systems and solutions and world-class service and support to government, industry and academia. Cray technology enables scientists and engineers to not only meet existing and future simulation and analytics challenges but achieve remarkable breakthroughs by accelerating performance, improving efficiency and extending the capabilities of their most demanding applications.

Cray Computer GmbH

Hochbergerstrasse 60C

4057 Basel

http://www.cray.com

The Swiss Personalized Health Network (SPHN) is an national initiative promoting the development of personalized health research. The Data Coordination Centre (DCC), operated by the SIB Swiss Institute of Bioinformatics (SIB), coordinates activities in the fields of clinical medicine, academic research and IT to achieve nationwide interoperability of health data.

SPHN

Hochbergerstrasse 60C

4057 Basel

dcc@sib.swiss

https://dcc.sib.swiss

Douglas Connect manages collaborative projects to achieve goals in scientific research, infrastructure development or service provision. Douglas Connect acts both as the initiator of independent research projects (eg. in Discovery Informatics, Knowledge Management, Life Sciences, Drug Safety, Environmental Chemistry, Risk Assessment) and as a provider of integrated services for corporate clients in these areas.

Douglas Connect GmbH

Hochbergerstrasse 60C

4057 Basel

http://www.douglasconnect.com

FGen is a service provider for biotechnology, life-sciences, and industry. The company was founded in 2011 by Prof. Sven Panke (Bioprocess Laboratory of the Department of Biosystems Science and Engineering of the ETH Zurich in Basel) and a number of his scientific fellows. FGen develops and performs high throughput experiments and assays on a contract basis for its customers from biotech, pharma, and chemical industries.

FGen GmbH

Hochbergerstrasse 60C

4057 Basel

http://www.fgen.ch

Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program, the investigational drug PEGPH20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. By breaking down potential barriers to treating cancer, PEGPH20 may help make existing treatments more effective by allowing therapies to reach the tumor.

Halozyme Switzerland GmbH

Hochbergerstrasse 60C

4057 Basel

http://www.halozyme.com

Making patient data smart - HCSG offers solutions for digital precision medicine.

We combine medical data with psychosocial data creating actionable information and risk predictions to improve individual health outcomes. Our highly flexible IT platform allows large scale implementation for a multitude of patient conditions and care situations.

Health Care Systems GmbH (HCSG)

Hochbergerstrasse 60C

4057 Basel

http://www.hcsg.de

Hutman Diagnostics is an in Vitro Diagnostics Product Development and Portfolio Management Company in particular, Hutman Diagnostics develops next generation diagnostic kits for life-threatening pathogens so far diagnosed mainly by classical culture. The new diagnostics shorten the time for medical decision to less than 4 hours while having inclusivity of nearly 100%. This will save health costs and shorten the time to cure.

Hutman Diagnostics AG

Hochbergerstrasse 60C

4057 Basel

http://www.hutman.ch

Intilaris LifeSciences is a life science company focusing on productivity improvements and optimizations in Clinical development of pharmaceutical companies. The company provides GCP consulting and develops tools and systems that will lead to better utilization of the current resources and optimization of the clinical development processes. The customers of intilaris LifeSciences are the Clinical Development organizations of research oriented pharmaceutical companies. To a wider extend, intilaris LifeSciences servs the Clinical Development organizations of research oriented biotechnology companies as well.

Intilaris LifeSciences GmbH

Hochbergerstrasse 60C

4057 Basel

http://www.intilaris.com

KINARUS AG is a private company located in Basel. We identify and develop differentiated medicines for diseases linked to stress related inflammatory pathways by scientific cross disease area target assessment.

KINARUS AG

Hochbergerstrasse 60C

4057 Basel

http://www.kinarus.com

NBE-Therapeutics is a new Swiss Life-Sciences company focused on the development of novel antibody-based therapeutics. NBE-Therapeutics utilizes a portfolio of in-house developed, externally acquired, and in-licensed novel patent families for the development of novel, best-in-class antibody drug conjugates (ADCs), that can specifically target cancer cells for destruction.

NBE-Therapeutics GmbH

Hochbergerstrasse 60C

4057 Basel

http://www.NBE-Therapeutics.com

PIQUR Therapeutics is a privately owned biopharmaceutical company, headquartered in Basel, Switzerland, that is pioneering the development of a novel class of targeted therapeutics. PIQUR is dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients.

The company was founded in 2011 as a spin-off of the University of Basel (Switzerland) to develop best-in-class, new generation cancer therapeutics targeting the PI3K-Akt-mTOR pathway. With its next generation agents, PIQUR is confident to be the leader in the development of drugs tackling the PI3K cancer pathway.

PIQUR AG

Hochbergerstrasse 60C

4057 Basel

http://www.piqur.com

Ramirez Engineering GmbH is a Hard- & Firmware Engineering company, specialized in standard and custom specific developments. In addition to devices for Industrial applications, we are also specialized in developing and manufacturing KNX devices, the worldwide standard for home and building control. In this way, we help reducing energy waste in Offices and Hotels Worldwide.

 

Ramirez Engineering GmbH

Hochbergerstrasse 60C

4057 Basel

Ridgeline is Versant’s newest discovery engine and has laboratories in Basel Technology Park. Ridgeline’s leadership team hails from Roche and has a proven track record in drug development.

Ridgeline Therapeutics AG

Hochbergerstrasse 60C

4057 Basel

Strekin AG is a private company located in Basel. We identify and develop differentiated medicines for diseases linked to stress related inflammatory pathways by scientific cross disease area target assessment.

STREKIN AG

Hochbergerstrasse 60C

4057 Basel

http://www.strekin.com

TargImmune Therapeutics AG is a startup company established in March 2016 in Basel, Switzerland. TargImmune is developing a novel cancer-targeted platform technology CTPIC in the field of immuno-oncology and personalized therapy.

TargImmune Therapeutics AG

Hochbergerstrasse 60C

4057 Basel

Texelia delivers IT expertise and project management to the most demanding organizations. By helping leaders in research, innovation and high-quality delivery, we contribute to the production of common goods which are central to sustainable well-being, such as health, mobility and public services.

Texelia means Technology, Excellence and Accuracy: it is the new name of Swiss ventures with a 25 years history of customer satisfaction in the pharmaceutical, chemical and nutrition industries as well as in transport and public administrations. Our clients are renowned organizations with a worldwide reach and reputation.

Texelia AG

Hochbergerstrasse 60C

4057 Basel

+41 61 638 23 80

www.texelia.com

VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.

Vaximm AG

Hochbergerstrasse 60C

4057 Basel

http://www.vaximm.com